1. Academic Validation
  2. Structure-activity relationships of a series of analogues of the RFamide-related peptide 26RFa

Structure-activity relationships of a series of analogues of the RFamide-related peptide 26RFa

  • J Med Chem. 2011 Jul 14;54(13):4806-14. doi: 10.1021/jm200418c.
Olivier Le Marec 1 Cindy Neveu Benjamin Lefranc Christophe Dubessy Jean A Boutin Jean-Claude Do-Régo Jean Costentin Marie-Christine Tonon Manuel Tena-Sempere Hubert Vaudry Jérôme Leprince
Affiliations

Affiliation

  • 1 INSERM U982, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, European Institute for Peptide Research (IFRMP 23), Cell Imaging Platform (PRIMACEN), University of Rouen, 76821 Mont-Saint-Aignan, France.
Abstract

26RFa is a new member of the RFamide peptide family that has been identified as the endogenous ligand of the orphan GPCR GPR103. As the C-terminal heptapeptide (26RFa((20-26))) mimics the action of the native peptide on food intake and gonadotropin secretion in rodents, we have synthesized a series of analogues of 26RFa((20-26)) and measured their potency to induce [CA(2+)](i) mobilization in Gα(16)-hGPR103-transfected CHO cells. Systematic replacement of each residue by an alanine (Ala scan) and its D-enantiomer (D scan) showed that the last three C-terminal residues were very sensitive to the substitutions while position 23 tolerated rather well both modifications. Most importantly, replacement of Ser(23) by a norvaline led to an analogue, [Nva(23)]26RFa((20-26)), that was 3-fold more potent than the native heptapeptide. These new pharmacological data, by providing the first information regarding the structure-activity relationships of 26RFa analogues, should prove useful for the rational design of potent GPR103 receptor ligands with potential therapeutic application.

Figures